drugset
drugset / Trial / NCT02870907

Adjuvant Treatment in Extensive Unilateral Retinoblastoma Primary Enucleated (RB SFCE 2009)

NCT02870907 ↗

Phase 2 Active not recruiting 195 enrolled Institut Curie
Non-randomizedParallel-groupOpen-labelTreatment

Summary

Postoperative Treatment of Unilateral Retinoblastoma After Primary Enucleation according to histopathological risk factors of the International Retinoblastoma Staging Working Group.

Timeline

Start
2010-03-18
Primary completion
2031-03-01
Completion
2031-03-01

Drugs

EvaluationDrugModalityDoseRoute
Subject Carboplatin Small molecule 7 unknown Intravenous
Subject Carboplatin Small molecule 160 mg/m2 Intravenous
Subject Carboplatin Small molecule 560 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 300 mg/m2 Intravenous
Subject Cyclophosphamide Other / unclassified 1000 mg/m2 Intravenous
Subject Etoposide Small molecule 100 mg/m2 Intravenous
Subject Etoposide Small molecule 250 mg/m2 Intravenous
Subject Thiotepa Other / unclassified 15 mg Intrathecal
Subject Thiotepa Other / unclassified 300 mg/m2 Intrathecal
Subject Vincristine Small molecule 1.5 mg/m2 Intravenous

Indications

retinoblastoma